{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:45:19Z","timestamp":1792496719582,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.dsx.2022.102539","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:36:36Z","timestamp":1654868196000},"page":"102539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Shivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102539_bib1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3748\/wjg.v28.i8.775","article-title":"Clinical implications of diabetes in chronic liver disease: diagnosis, outcomes and management, current and future perspectives","volume":"28","author":"Garc\u00eda-Compe\u00e1n","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dsx.2022.102539_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijem.IJEM_31_18","article-title":"Neck circumference to height ratio is a reliable predictor of liver stiffness and nonalcoholic fatty liver disease in prediabetes","volume":"22","author":"Mondal","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2022.102539_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XCE.0000000000000201","article-title":"Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us?","volume":"9","author":"Al-Mrabeh","year":"2020","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102539_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.dsx.2022.102539_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102539_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-018-1708-z","article-title":"The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis","volume":"62","author":"Li","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.dsx.2022.102539_bib7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"NN9931-4296 investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102539_bib8","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102539_bib9","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: a meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dsx.2022.102539_bib10","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102539_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.dsx.2022.102539_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.dsx.2022.102539_bib13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dsx.2022.102539_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2022.102539_bib15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102539_bib16","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s40200-021-00899-9","article-title":"Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists","volume":"20","author":"Okamoto","year":"2021","journal-title":"J\u00a0Diabetes Metab Disord"},{"key":"10.1016\/j.dsx.2022.102539_bib17","article-title":"Additional effect of luseogliflozin on semaglutide in nonalcoholic steatohepatitis complicated by type 2 diabetes mellitus: an open-label, randomized, parallel-group study","volume":"21","author":"Miyake","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.dsx.2022.102539_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dsx.2022.102539_bib19","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2022.102539_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/dme.12039","article-title":"Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes","volume":"30","author":"Taylor","year":"2013","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2022.102539_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102436","article-title":"Oral semaglutide in type 2 diabetes mellitus: comprehensive review, critical appraisal and clinical consideration of its use in India","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dsx.2022.102539_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/jcpt.13574","article-title":"Clinical review of subcutaneous semaglutide for obesity","volume":"47","author":"Phillips","year":"2022","journal-title":"J\u00a0Clin Pharm Ther"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:19:03Z","timestamp":1761729543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1871402122001539"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102539","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102539"}}